Review
Copyright ©2014 Baishideng Publishing Group Inc.
World J Rheumatol. Nov 12, 2014; 4(3): 22-34
Published online Nov 12, 2014. doi: 10.5499/wjr.v4.i3.22
Table 4 Summary of clinical trials investigating the effects of creatine supplementation on body composition and physical function
ConditionTreatment armSupplementation periodControl armBody composition changesPhysical function changesOther effectsRef.
Osteoarthritisn = 1810 g/d pre surgery; 5 g/d for 30 d post-surgeryvs PL (n = 19) (dextrose)2% BF, 2FM, 3LM (CSA), 3BW3Strength3PCr[106]
Fibromyalgian = 1620 g/d for 5 d followed by 5 g/d for 16 wkvs PL (n = 16) (dextrose)Not measured1Strength3QoL scores, 3Pain, 3Cognition, 1PCr[109]
Cancer (cachexia)n = 16 (colorectal cancer)20 g/d for 5 d followed by 5 g/d for 8 wkvs PL (n = 15) (cellulose)3LM1Strength3QoL scores[118]
n = 9 (adolescents with leukaemia (acute lymphoblastic)2 sets of 8 wk (with a 6 wk wash out in-between)vs control “natural history group” (n = 50)3LM, 2%BFNo details3Bone mineral content[119]
Duchenne muscular dystrophyn = 18 (adolescents)5 g/d for 8 wkvs PL (n = 15) (vitamin C)No details1Strength1PCr[113]
n = 15 (adolescents)5 g/d for 24 wkvs PL (n = 16) (cocoa powder)No details3Strength, 3Objective function tests[116]
n = 30 (adolescents)0.10 g per kg/d for 16 wkCross-over design (PL group dextrose)1LM1Strength2Bone breakdown markers[112]
n = 15 (adolescents) (12 with DMD and 3 with Becker dystrophy)3 g/d for 13 wkCross-over design (PL group maltodextrin)No details1Strength (MVC), 1Fatigue resistance[62]
Mytonic muscular dystrophy 1 (DM1)n = 345 g/d for 36 wkCross-over design (PL group dextrose)3LM3Strength, 3Objective function tests[115]
n = 3410.6 g/d for 10 d followed by 5.3 g/d for 45 dCross-over design (PL group cellulose)3LM3Strength3ADL, 3QoL scores[114]
Mytonic muscular dystrophy 2 (DM2)n = 1010 g/d for 13 wkvs PL (n = 10)No details3Strength3QoL scores[117]